Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)
Article
Wefel, Jeffrey S, Armstrong, Terri S, Pugh, Stephanie L et al. (2021). Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)
. NEURO-ONCOLOGY, 23(7), 1125-1138. 10.1093/neuonc/noab011
Wefel, Jeffrey S, Armstrong, Terri S, Pugh, Stephanie L et al. (2021). Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)
. NEURO-ONCOLOGY, 23(7), 1125-1138. 10.1093/neuonc/noab011
Wefel, Jeffrey S; Armstrong, Terri S; Pugh, Stephanie L; Gilbert, Mark R; Wendland, Merideth M; Brachman, David G; Roof, Kevin S; Brown, Paul D; Crocker, Ian R; Robins, H Ian; Hunter, Grant; Won, Minhee; Mehta, Minesh P